May 24, 2019

Novocure to Participate in the Jefferies 2019 Global Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City. Mr. Doyle’s presentation will begin at 9 a.m. EDT and will be followed by a… Read More
learn more
May 23, 2019

FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma

NovoTTF-100L, a Tumor Treating Fields delivery system, is the first FDA-approved mesothelioma treatment in more than 15 years In the STELLAR trial, malignant pleural mesothelioma patients treated with Tumor Treating Fields plus platinum-based chemotherapy experienced a median overall survival of 18.2 months ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure… Read More
learn more
May 10, 2019

Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM). Proposed LCDs are subject to… Read More
learn more
May 2, 2019

Novocure Reports First Quarter 2019 Financial Results and Provides Company Update

Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018 Mesothelioma humanitarian device exemption application under FDA review Enrollment ongoing in four phase 3 pivotal trials, creating a significant market expansion opportunity in… Read More
learn more